Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

Blanca Homet MorenoDepartment of Medicine; Division of Hematology/Oncology; University of California, Los Angeles (UCLA); Los Angeles, CAUSA

Stephen MokDepartment of Molecular and Medical Pharmacology; University of California, Los Angeles (UCLA); Los Angeles, CAUSA

Begonya Comin-AnduixThe Jonsson Comprehensive Cancer Center (JCCC); University of California, Los Angeles (UCLA); Los Angeles, CAUSA;Surgery; Division of Surgical Oncology; University of California, Los Angeles (UCLA); Los Angeles, CAUSA

Siwen Hu-LieskovanDepartment of Medicine; Division of Hematology/Oncology; University of California, Los Angeles (UCLA); Los Angeles, CAUSA

Antoni RibasDepartment of Medicine; Division of Hematology/Oncology; University of California, Los Angeles (UCLA); Los Angeles, CAUSA;Department of Molecular and Medical Pharmacology; University of California, Los Angeles (UCLA); Los Angeles, CAUSA;The Jonsson Comprehensive Cancer Center (JCCC); University of California, Los Angeles (UCLA); Los Angeles, CAUSA;Surgery; Division of Surgical Oncology; University of California, Los Angeles (UCLA); Los Angeles, CAUSACorrespondence[email protected]

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

Supplemental_Material.zip

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

Supplemental_Material.zip

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date